Shots: The approval is based on the results of P-III PARADIGMS study assessing Gilenya (0.5mg/ 0.25mg, qd) vs Extavia (interferon beta-1a, qw) in 215 patients with MS aged 10 to <18 yrs, across 80 centers and 25 countries P-III PARADIGMS study Results: annualized relapse rates by 82%; relapse-free @ 24 months (85.7% vs 38.8%); reduction […]Read More
